FDA Brief

Warning letters Drugs

FDA warning letter to

USApeptide.com

High riskIssued Feb 26, 2025Posted Mar 11, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Germany-based USApeptide.com that it sells unapproved and misbranded semaglutide and tirzepatide drugs to U.S. consumers online.

What happened

FDA reviewed the website www.usapeptide.com and found semaglutide and tirzepatide products offered for sale with claims that they are intended for human use, despite “research use only” disclaimers. FDA said the products are new drugs without approved applications and prescription drugs offered without a prescription. The letter also noted the products are intended for injection and the site sells bacteriostatic water and insulin syringes.

What FDA found

  1. FDA says the semaglutide products are unapproved new drugs because no FDA-approved application is in effect for them.

    FD&C Act sections 505(a) and 301(d) [21 U.S.C. §§ 355(a), 331(d)]
  2. FDA says the tirzepatide products are unapproved new drugs because no FDA-approved application is in effect for them.

    FD&C Act sections 505(a) and 301(d) [21 U.S.C. §§ 355(a), 331(d)]
  3. FDA says the labeling lacks adequate directions for use, so the drugs are misbranded.

    FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)] and section 301(a) [21 U.S.C. § 331(a)]
  4. FDA says offering prescription drugs without requiring a prescription misbrands them while held for sale.

    FD&C Act sections 503(b)(1) and 301(k) [21 U.S.C. §§ 353(b)(1), 331(k)]
  5. FDA says website claims show the products are intended as drugs for human use despite “research use only” language.

    FD&C Act section 201(g) [21 U.S.C. § 321(g)]
  6. FDA says the products are intended for injection, which can bypass natural defenses and pose serious infection risks.

What FDA wants

FDA asks USApeptide.com to stop offering any unapproved and misbranded drugs for sale to U.S. consumers. It also asks for a written response within 15 working days describing corrective steps and documentation, or an explanation for any delay.

Who should pay attention

  • online sellers shipping drug products to U.S. consumers
  • consumers and clinics buying GLP-1 products online
  • companies handling semaglutide or tirzepatide products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk
  4. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk